Sangui Bio Pty Ltd and Colonoscopy Clinic Pty Ltd are pleased to announce their collaborative research and trials partnership. This partnership will see Colonoscopy Clinic inform patients about the Sangui Bio Bio-ECON (Biomarkers of Early Colorectal Neoplasia) trial across its patient base and referral relationships in Queensland.
Speaking in Brisbane, A/Prof Dan Worthley said “At Colonoscopy Clinic we are working towards a future where no Australian dies of colorectal cancer. Part of this journey is developing new strategies to detect, prevent and treat colorectal cancer. At Colonoscopy Clinic we coordinate a high volume of quality community colonoscopy, we curate a detailed clinical database, and we are committed to colorectal cancer research. These three factors, together, help to deliver real research and clinical value to our patients, our partners, and our community.”
Dr Ben Herbert, the Sangui Bio Chief Scientist said “We are incredibly pleased to be working with the Colonoscopy Clinic to fast-track the next stage of our Colorectal Neoplasia study. Sangui Bio has generated promising preliminary data with our academic collaborator, Prof. Mark Molloy at the University of Sydney. The next stage of the study requires a significant increase in recruitment and the Colonoscopy Clinic are the ideal partners to enable that through their engagement with a large number of potential study participants.”
Prof. Mark Molloy, the Lawrence Penn Chair of Bowel Cancer Research at the University of Sydney said, “Patient self-sampling of blood is an innovative area of diagnostics that may encourage greater participation in screening to prevent diseases such as bowel cancer. It is exciting that the Bio-ECON study can now move forward at pace to evaluate our initial findings.”